BioMarin posts Q3 2026 revenue above $1 billion but trims full‑year outlook
BioMarin Pharmaceutical reported third‑quarter 2026 revenue of $1.025 billion, up 32% year‑over‑year, and non‑GAAP earnings of $0.23 per share. The company lowered its full‑year 2026 revenue guidance by $50 million and its earnings guidance to $2.80‑$3.10 per share, citing order‑timing uncertainty and charges from two acquired in‑process R&D assets. Management highlighted accelerated cost synergies from the Amicus acquisition and announced a new investigational Fabry disease asset.
Why it matters
The reduced full‑year guidance signals lower near‑term revenue growth, which may affect analyst forecasts and investor expectations for BioMarin’s 2026 earnings. The company’s expectation of faster Amicus cost synergies could partially offset the guidance cut, but the net impact on earnings per share remains uncertain.
Key facts
- 1Q3 2026 total revenues were $1.025 billion, a 32% increase versus the same quarter in 2025. prnewswire.com
- 2Non‑GAAP EPS for the quarter was $0.23 per share. seekingalpha.com
- 3Full‑year 2026 revenue guidance was lowered by $50 million. investing.com
- 4Full‑year 2026 earnings per share guidance was revised to $2.80‑$3.10. investing.com
- 5The guidance cut was attributed to order‑timing uncertainty and the impact of two acquired in‑process R&D charges. stocktitan.net
- 6Management expects accelerated cost synergies from the Amicus Therapeutics acquisition. investing.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.